FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2138537138> ?p ?o ?g. }

• W2138537138 endingPage "1632" @default.
• W2138537138 startingPage "1627" @default.
• W2138537138 abstract "Preclinical studies have demonstrated the synergistic anti-tumour activity of combination therapy with the oral cytostatics, 5′-deoxy-5-fluorouridine (5′-DFUR) and cyclophosphamide (CPA), in human breast cancer xenograft models. This study was performed to evaluate the efficacy and safety of this oral combination chemotherapy in the treatment of metastatic breast cancer. In all, 101 patients with metastatic breast cancer were enrolled in the study, and the data for 94 eligible patients of these were evaluated. The patients received twice daily oral combinations of 5′-DFUR (1200 mg/body/day) and CPA (100 mg/body/day) for 2 weeks, followed by a 1-week rest period. After a median of 19 treatment cycles (range 1–66 cycles), 16 patients (17.0%) had a complete response, and 40 patients (42.6%) had partial responses. The response rate was 59.6% (95% CI, 49.0–69.6%). The median time to progression and overall survival times were 11.7 and 40.3 months, respectively. The toxicity was mild and tolerable, and the related grade 3/4 clinical adverse effects consisted of haematological toxicity in 21 patients (22%) and nonhaematological toxicity in five patients (5%). These results suggest that the oral combination chemotherapy of 5′-DFUR and CPA has low toxicity and is a novel, very convenient and effective treatment for metastatic breast cancer." @default.
• W2138537138 created "2016-06-24" @default.
• W2138537138 creator A5018902931 @default.
• W2138537138 creator A5023783988 @default.
• W2138537138 creator A5025267123 @default.
• W2138537138 creator A5029055977 @default.
• W2138537138 creator A5038018993 @default.
• W2138537138 creator A5055758268 @default.
• W2138537138 creator A5058409424 @default.
• W2138537138 creator A5062939633 @default.
• W2138537138 creator A5086367318 @default.
• W2138537138 date "2003-10-28" @default.
• W2138537138 modified "2023-10-18" @default.
• W2138537138 title "The potential for oral combination chemotherapy of 5′-deoxy-5-fluorouridine, a 5-FU prodrug, and cyclophosphamide for metastatic breast cancer" @default.
• W2138537138 cites W1488362191 @default.
• W2138537138 cites W1530403388 @default.
• W2138537138 cites W1571748472 @default.
• W2138537138 cites W1582021390 @default.
• W2138537138 cites W1723840722 @default.
• W2138537138 cites W1973635345 @default.
• W2138537138 cites W2025551098 @default.
• W2138537138 cites W2029260618 @default.
• W2138537138 cites W2038563885 @default.
• W2138537138 cites W2044970916 @default.
• W2138537138 cites W2071205059 @default.
• W2138537138 cites W2113550611 @default.
• W2138537138 cites W2131770017 @default.
• W2138537138 cites W2138577761 @default.
• W2138537138 cites W2151134466 @default.
• W2138537138 cites W2159252892 @default.
• W2138537138 cites W2176579253 @default.
• W2138537138 cites W2342726154 @default.
• W2138537138 cites W2401318060 @default.
• W2138537138 cites W2411049219 @default.
• W2138537138 cites W2471219468 @default.
• W2138537138 cites W2473787171 @default.
• W2138537138 cites W2612574275 @default.
• W2138537138 cites W937265717 @default.
• W2138537138 doi "https://doi.org/10.1038/sj.bjc.6601350" @default.
• W2138537138 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/2394400" @default.
• W2138537138 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/14583760" @default.
• W2138537138 hasPublicationYear "2003" @default.
• W2138537138 type Work @default.
• W2138537138 sameAs 2138537138 @default.
• W2138537138 citedByCount "17" @default.
• W2138537138 countsByYear W21385371382012 @default.
• W2138537138 countsByYear W21385371382013 @default.
• W2138537138 countsByYear W21385371382015 @default.
• W2138537138 countsByYear W21385371382020 @default.
• W2138537138 countsByYear W21385371382021 @default.
• W2138537138 crossrefType "journal-article" @default.
• W2138537138 hasAuthorship W2138537138A5018902931 @default.
• W2138537138 hasAuthorship W2138537138A5023783988 @default.
• W2138537138 hasAuthorship W2138537138A5025267123 @default.
• W2138537138 hasAuthorship W2138537138A5029055977 @default.
• W2138537138 hasAuthorship W2138537138A5038018993 @default.
• W2138537138 hasAuthorship W2138537138A5055758268 @default.
• W2138537138 hasAuthorship W2138537138A5058409424 @default.
• W2138537138 hasAuthorship W2138537138A5062939633 @default.
• W2138537138 hasAuthorship W2138537138A5086367318 @default.
• W2138537138 hasBestOaLocation W21385371381 @default.
• W2138537138 hasConcept C108215921 @default.
• W2138537138 hasConcept C121608353 @default.
• W2138537138 hasConcept C126322002 @default.
• W2138537138 hasConcept C143998085 @default.
• W2138537138 hasConcept C197934379 @default.
• W2138537138 hasConcept C2775930923 @default.
• W2138537138 hasConcept C2776694085 @default.
• W2138537138 hasConcept C2776755627 @default.
• W2138537138 hasConcept C29730261 @default.
• W2138537138 hasConcept C530470458 @default.
• W2138537138 hasConcept C71924100 @default.
• W2138537138 hasConcept C90924648 @default.
• W2138537138 hasConcept C98274493 @default.
• W2138537138 hasConceptScore W2138537138C108215921 @default.
• W2138537138 hasConceptScore W2138537138C121608353 @default.
• W2138537138 hasConceptScore W2138537138C126322002 @default.
• W2138537138 hasConceptScore W2138537138C143998085 @default.
• W2138537138 hasConceptScore W2138537138C197934379 @default.
• W2138537138 hasConceptScore W2138537138C2775930923 @default.
• W2138537138 hasConceptScore W2138537138C2776694085 @default.
• W2138537138 hasConceptScore W2138537138C2776755627 @default.
• W2138537138 hasConceptScore W2138537138C29730261 @default.
• W2138537138 hasConceptScore W2138537138C530470458 @default.
• W2138537138 hasConceptScore W2138537138C71924100 @default.
• W2138537138 hasConceptScore W2138537138C90924648 @default.
• W2138537138 hasConceptScore W2138537138C98274493 @default.
• W2138537138 hasIssue "9" @default.
• W2138537138 hasLocation W21385371381 @default.
• W2138537138 hasLocation W21385371382 @default.
• W2138537138 hasLocation W21385371383 @default.
• W2138537138 hasLocation W21385371384 @default.
• W2138537138 hasOpenAccess W2138537138 @default.
• W2138537138 hasPrimaryLocation W21385371381 @default.
• W2138537138 hasRelatedWork W144521535 @default.
• W2138537138 hasRelatedWork W2031329688 @default.
• W2138537138 hasRelatedWork W2092771806 @default.
• W2138537138 hasRelatedWork W2166237570 @default.

• next